Cardiac surgery and antiplatelet therapy by Malm, Carl Johan
CARDIAC SURGERY AND 
ANTIPLATELET THERAPY 
  
 
 
 
Carl Johan Malm 
 
 
 
Department of Molecular and Clinical Medicine 
Institute of Medicine 
Sahlgrenska Academy at University of Gothenburg 
 
 
 
 
 
 
 
Gothenburg 2017 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Cardiac surgery and antiplatelet therapy 
© Carl Johan Malm 2017 
carl.malm@vgregion.se 
 
ISBN 978-91-629-0123-3 (print) 
ISBN 978-91-629-0124-0 (PDF) 
http://hdl.handle.net/2077/50863 
 
Printed in Gothenburg, Sweden 2017 
Ineko AB 
  
Cardiac surgery and antiplatelet 
therapy 
Carl Johan Malm 
Department of Molecular and Clinical Medicine, Institute of Medicine 
Sahlgrenska Academy at University of Gothenburg 
Gothenburg, Sweden 
ABSTRACT 
Background 
Dual antiplatelet therapy (DAPT) with acetylsalicylic acid (ASA) and a P2Y12 
inhibitor improves outcome in acute coronary syndrome (ACS). In the subset 
of ACS patients undergoing urgent cardiac surgery, ongoing or recently 
discontinued DAPT is associated with increased risk of bleeding. Postoperative 
DAPT in ACS patients after coronary artery bypass grafting (CABG) may 
improve graft patency and short-term survival. The aim of this project was to 
study ACS patients undergoing cardiac surgery and how DAPT with ASA and 
ticagrelor influences perioperative bleeding risks, how bleeding can be treated, 
and to investigate if survival after CABG is influenced by antiplatelet therapy. 
Methods 
In paper I, recovery of platelet function after discontinuation of ticagrelor was 
investigated using multiple-electrode aggregometry (MEA) in ACS patients 
awaiting CABG. The effect of platelet concentrate at different discontinuation 
times was also studied. Paper II was a prospective observational study of 
patients undergoing cardiac surgery with ongoing or recently discontinued 
ticagrelor treatment. The relationship between preoperative MEA and 
postoperative bleeding was investigated. In paper III, MEA was used to 
investigate the effect of aprotinin and tranexamic acid on platelet function in 
ACS patients with ongoing DAPT using ASA and ticagrelor. Paper IV was a 
nationwide study of all ACS patients undergoing isolated CABG surgery during 
a four-year period. The influence of postoperative antiplatelet therapy on one-
year mortality was investigated using propensity score matching. 
Results 
Mean platelet ADP-induced aggregation increased gradually after ticagrelor 
discontinuation and reached normal values after 72–96 hours. There was a 
large inter-individual variability. Platelet concentrate did not improve ADP-
induced aggregation at any time, but markedly increased arachidonic acid-
 induced aggregation at all time points. Preoperative ADP-induced aggregation 
predicted severe bleeding complications, with an optimal cut-off of 22 
aggregation units. Aprotinin, but not tranexamic acid increased ADP-induced 
aggregation in patients with ongoing DAPT using ASA and ticagrelor. 
Postoperative treatment with ASA + ticagrelor was associated with a reduced 
one-year mortality compared to ASA only (hazard ratio 0.42, p=0.020). 
Conclusions 
Platelet function testing improved the assessment of the operative risk in 
ticagrelor treated patients. Platelet transfusion have no or limited effect in 
treating bleeding in patients with recent ticagrelor therapy. From a platelet 
function perspective, aprotinin may be preferred over TA in ticagrelor treated 
patients. Survival after CABG in ACS patients is likely influenced by 
postoperative antiplatelet therapy, with improved outcome associated with 
ticagrelor treatment.  
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SAMMANFATTNING PÅ SVENSKA 
Syrebrist i hjärtmuskeln är den vanligaste dödsorsaken i Sverige och 
världen. Den orsakas vanligen av blodproppar som bildas vid 
åderförkalkning i hjärtats kranskärl. Sprickor i blodkärlens innersta 
skikt orsakar aktivering av trombocyter (blodplättar) som klumpar ihop 
sig och bildar blodproppar. När blodet inte kan passera drabbas 
patienten av ett akut koronart syndrom (AKS) som kan leda till 
hjärtinfarkt och i värsta fall hjärtstopp. Prognosen hos patienter med 
AKS förbättras om man hämmar trombocytfunktionen. Ticagrelor är en 
relativt ny trombocythämmare och används i Sverige som tillägg till 
acetylsalicylsyra (ASA) hos de flesta patienter med AKS. 
De flesta patienter med AKS behandlas med ballongsprängning eller 
bara läkemedel, men en av tio patienter behöver genomgå en öppen 
hjärtoperation, oftast i form av en bypassoperation. Om operationen 
sker kort tid efter utsättning av ticagrelor är patienterna mer benägna 
att blöda. Vid allvarlig blödning ökar risken för andra komplikationer 
och död. Denna risk måste vägas mot risken för ny infarkt om man 
skjuter upp operationen. 
I första delarbetet undersöktes återhämtningen av trombocytfunktionen 
efter utsättning av ticagrelor hos patienter som väntade på 
bypassoperation. Mätningar genomföres efter 12, 24, 48, 72 och 96 
timmar. I genomsnitt sågs en återhämtning efter tre dygn, men det fanns 
en stor variation mellan olika patienter. Vissa hade dålig 
trombocytfunktion fyra dygn efter utsättning, medan andra återhämtat 
funktionen redan efter 24–48 timmar. Försök att motverka ticagrelors 
hämning genom tillsats av nya trombocyter var inte framgångsrikt. 
I det andra delarbetet undersöktes om mätning av trombocytfunktion 
före operation kunde användas för att avgöra risken för allvarlig 
blödning. Alla undersökta patienter hade behandlats med ticagrelor 
inom 5 dagar från operation. Med hjälp av testresultaten kunde risken 
för allvarlig blödning bestämmas med rimlig visshet. Ett tröskelvärde 
kunde fastställas när risken för allvarlig blödning var hög. 
I syfte att minska blödning får patienter som hjärtopereras rutinmässigt 
läkemedel som hämmar nedbrytningen av blodproppar (s.k. 
fibrinolyshämmare), vanligen i form av tranexamsyra. En annan 
fibrinolyshämmare, aprotinin, kan ibland påverka trombocyterna. I 
 delstudie tre testades trombocytfunktionen hos patienter med pågående 
ticagrelor behandling. Efter tillsats av aprotinin förbättrades 
trombocytfunktionen signifikant, medan tranexamsyra inte hade någon 
sådan effekt. Detta talar för att aprotinin kan vara att föredra hos 
patienter som behandlats med ticagrelor. 
För att förhindra nya proppar efter en bypassoperation rekommenderas 
åter trombocythämning med två olika läkemedel, men övertygande 
bevis om vinsten med dubbel behandling efter operation saknas, och 
majoriteten av alla patienter får bara ASA. I det fjärde delarbetet 
undersöktes alla patienter med AKS som genomgått bypassoperation i 
Sverige under 2012–2015 med syftet att undersöka om 
trombocythämning påverkade överlevnad efter operation. Hos dem som 
fick ticagrelor var risken för död mer än halverad under första året.  
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1 INTRODUCTION 
1.1 Ischaemic heart disease 
Coronary thrombosis was recognized as a cause of death during the 
nineteenth century, but it was long regarded as a medical curiosity1. 
Today, ischaemic heart disease (IHD) is the leading cause of death, both 
worldwide and in Sweden. Despite improvements in treatment and 
outcome in recent years, more than seven million persons succumb to 
the disease every year2. In Sweden, more than 13% of deaths are caused 
by IHD, although there are large regional variations, with annual death 
rates ranging from 76–173 deaths per 100,000 in different counties3.  
IHD can be classified as chronic, stable angina or as an acute coronary 
syndrome (ACS). The former patients have stable symptoms and no 
evidence of acute myocardial infarction. ACS is characterized by a 
sudden worsening of symptoms, usually due to formation of an intra-
coronary thrombus. ACS is further categorized depending on the degree 
of coronary obstruction and associated myocardial ischaemia. A 
partially occlusive thrombus is the usual cause of the closely related 
syndromes unstable angina (UA) and non-ST-segment elevated 
myocardial infarction (nSTEMI), the difference being that UA patients 
do not have myocardial necrosis. When the thrombus completely 
obstructs the epicardial coronary artery, an ST-segment elevation 
myocardial infarction (STEMI) ensues, in which the ischaemia and 
resulting myocardial necrosis is more severe. 
At the beginning of the twentieth century, some insight was gained into 
the causal relationship between coronary sclerosis, coronary 
thrombosis, and myocardial necrosis4. Today, we understand that intra-
coronary thrombi may form when blood comes in contact with areas of 
blood vessels where the endothelial lining is disrupted due to underlying 
atherosclerotic plaques. This leads to the activation of platelets and 
coagulation systems, which form thrombi that reduce blood flow and 
may cause distal embolization5. This pathophysiology provides the basis 
for the anti-thrombotic and fibrinolytic therapies that have become so 
prevalent in the management of these patients in modern times.  
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1.2 Platelets 
Platelets were first described in the nineteenth century after the 
invention of the twin-lens microscope6. An understanding of the 
importance of platelets in the haemostasis of humans was gained from 
animal studies and clinical experience during the early twentieth 
century7. In a case reported from 1910, a young patient suffered from 
uncontrollable epistaxis. Coagulation time was normal, but the platelet 
count was markedly reduced (6,000/µL). After whole-blood transfusion, 
the bleeding ceased and the platelet count simultaneously rose 
dramatically. This illustrated the importance of adequate platelet 
function in bleeding patients, and also that normal coagulation tests do 
not ensure acceptable haemostasis in the presence of 
thrombocytopenia8.  
Between 1,000 and 3,000 platelets are formed as subcellular, disk-
shaped fragments (2‒5 µm in diameter, 0.5 µm in thickness) from a 
mega-karyocyte residing in the bone marrow9. After release into the 
bloodstream, platelets circulate for 7–10 days at a normal concentration 
of 150‒400 × 109/L. Platelets have no nucleus, but they do contain 
mRNA and a translation apparatus, and can therefore synthesize 
certain proteins10. They also have a cytoskeleton that enables changes in 
shape, mitochondria for generation of energy, and a large number of 
granules that contain protein receptors and signalling molecules. Old 
platelets are cleared from the circulation through phagocytosis in the 
spleen and liver.  
Due to their shape and small size, circulating platelets are pushed 
towards the vessel wall by the larger erythrocytes and leukocytes. This 
peripheral position is optimal for rapidly detecting and responding to 
vascular injury. Interactions with the vessel wall are also facilitated by 
the laminar blood flow being slower adjacent to the vessel wall11. 
Membrane receptors serve as contacts between platelets and their 
environment, and a wide range of agonists and adhesive proteins trigger 
platelet reactivity. Collagen, von Willebrand factor (vWF), thrombin, 
thromboxane A2, and adenosine diphosphate (ADP) are the most 
important platelet activators12. 
 
Carl Johan Malm 
3 
1.3 Haemostasis 
Haemostasis is the normal process for causing bleeding to stop13. It 
involves the coordinated effect of platelets, coagulation proteins in the 
blood, and endothelial and sub-endothelial tissue where expression of 
initiators of coagulation is found. Together, these systems interact to 
maintain the integrity of the blood circulation by creating a stable 
haemostatic thrombus plug. This blood clot is the result of both 
primary and secondary haemostasis, which are dependent on each other 
and can be regarded as concurrent.  
Primary haemostasis is initiated after circulating blood is exposed to an 
injury in the vessel wall. Platelets are captured from the blood through 
interaction with vWF, which is ubiquitously expressed in sub-
endothelial tissue. Stable adhesion requires additional interactions with 
collagen. This triggers an activation of the platelets with a rapid 
morphological change and release of granule contents, including 
coagulation factors, pro-inflammatory mediators, platelet activators, 
and vasoconstrictors. Expression of the surface receptor glycoprotein 
GP IIb/IIIa, with a high affinity for circulating fibrinogen, causes 
platelet-platelet aggregation. In addition, activation exposes the anionic 
phospholipid phosphatidylserine at the outer platelet surface; this 
facilitates the interaction of pro-coagulant proteins, leading to a burst 
of thrombin, fibrin formation and further platelet activation14. 
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Secondary haemostasis, also referred to as coagulation, is a process that 
results in insoluble cross-linked fibrin strands that stabilize the primary 
platelet plug (Figure 1). Coagulation is activated by extravascular tissue 
factor (TF), a ligand that is expressed in the tunica media of the vessel 
wall15. Factor VII and TF form a complex, which, through a cascade of 
reactions, amplifies the production of thrombin (activated factor II). 
Thrombin cleaves fibrino-peptides from fibrinogen, creating fibrin 
monomers which rapidly polymerize into insoluble fibrin strands.  
  
Figure 1.  Scanning electron microscopy of red blood cells trapped in fibrin 
strands interconnected by attached platelets. Magnification 5000x. Science 
Photo Library / Alamy Stock Photo, with permission.  
 
The breakdown of an established thrombus is called fibrinolysis. This 
process is also important in preventing excessive thrombus formation 
after activation of the coagulation system. It is mediated through the 
action of plasmin, which is generated from the zymogen plasminogen 
by either tissue plasminogen activator (tPA) or urokinase (uPA)16.  
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Plasmin is a serine protease that, among other functions, cleaves fibrin. 
Plasmin has a lysine-binding site to which it can attach and split the 
fibrin strand, resulting in the release of soluble fibrin degradation 
products (FDPs) such as d-dimer.  The coagulation and fibrinolytic 
systems are highly regulated and interrelated, to ensure balanced 
haemostasis16. 
1.4 Antithrombotic treatment  
An antithrombotic agent is a drug that reduces the formation of blood 
clots. Antiplatelet drugs limit the adhesion, aggregation, and activation 
of platelets. Anticoagulants limit the coagulation system and the 
formation of thrombin and fibrin strands. Thrombolytic drugs activate 
fibrinolysis to dissolve clots after they have formed. 
Antithrombotic drugs can reduce myocardial injury in patients with 
ACS. More potent drugs or a combination of multiple treatments may 
have an incremental effect in reducing coronary thrombus formation, 
but there is an increased risk of bleeding complications. Finding the 
optimal balance between reduced thrombus formation and increased 
bleeding risk requires accurate assessment of the respective risks, and 
can be a challenging in the clinical setting.  
1.4.1 Acetylsalicylic acid 
Acetylsalicylic acid (ASA) was originally developed in the nineteenth 
century as an analgesic and antipyretic medication. Its antithrombotic 
properties were observed much later –gastrointestinal bleeding was 
linked to ASA in 193817, and prolongation of the bleeding time by ASA 
was first demonstrated in the 1950s. In 1967, after noting his own 
increased bleeding from razor nicks when using ASA, Weiss 
demonstrated that ASA inhibits thrombus formation through inhibition 
of platelet aggregation initiated by connective tissue18.  
ASA irreversibly inhibits the enzyme cyclo-oxygenase (COX), which 
converts arachidonic acid to prostaglandin; this is in turn required for 
the synthesis of thromboxane A219. Platelets normally synthesize 
thromboxane A2 to create a positive feedback by stimulating and 
recruiting more platelets to the primary haemostatic plug20. 
In ACS, ASA was shown to be effective in pioneering trials, which 
demonstrated a relative risk reduction of approximately 25% regarding 
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vascular mortality21. The efficacy and safety of ASA has now been 
documented in over 70 randomized clinical trials, which have included 
more than 115,000 patients at variable risk of thrombotic 
complications of atherosclerosis22.  
Various doses of ASA have been tested in different clinical settings and 
over the whole spectrum of athero-thrombosis –from apparently 
healthy, low-risk individuals to patients presenting with an acute 
myocardial infarction. Life-long ASA is now recommended for all 
patients with ischaemic heart disease, including ACS patients without 
contraindications23. 
1.4.2 Dual antiplatelet therapy 
During the 1970s, in an effort to find new anti-inflammatory drugs, a 
number of compounds belonging to the thienopyridine group were 
synthesized and screened in animal models mimicking human 
pathologies. None of the thienopyridine compounds had anti-
inflammatory effects, but some displayed unexpected antiplatelet and 
antithrombotic effects after oral administration in rats.  
One of the most active compounds, ticlopidine, was evaluated further in 
clinical settings where platelet interactions with artificial surfaces could 
lead to thrombotic complications, such as mechanical circulatory 
support and haemodialysis. It was launched on the market in 1978 for 
these restricted indications24. 
During the 1990s, intra-coronary stenting after percutaneous 
transluminal coronary angioplasty (PTCA) was limited by the risk of 
thrombotic occlusion of the stents. ASA and anticoagulation therapy 
were used to improve the outcome, but resulted in an increased risk of 
haemorrhagic complications25. In these patients, increased platelet 
activation was found to be an independent predictor of stent occlusion, 
suggesting that platelets played a more central role in stent thrombosis 
than the coagulation system26. This triggered an increased interest in 
antiplatelet therapy, leading to a number of trials on the effect of dual 
antiplatelet therapy (DAPT)27. A marked decrease in the occurrence of 
stent thrombosis was demonstrated using ticlopidine in combination 
with ASA (ASA: 3.6%; DAPT: 0.5%; p = 0.001)28.   
Due to adverse side effects of ticlopidine29, a continued search for new 
drugs with a more favourable pharmacological profile was undertaken. 
More than a thousand ticlopidine analogues were synthesized and 
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tested in animals for their antiplatelet and antithrombotic effects. Eight 
of them were developed up to phase-1 studies in healthy volunteers and 
only the last one, PCR4099, proved to be clearly more active and better 
tolerated than ticlopidine24. After ten years of development and large 
clinical studies, PCR4099, or clopidogrel, was launched in 1998. 
Ticlopidine and clopidogrel require hepatic metabolism through a 
cytochrome P450- (CYP-) dependent pathway to form active 
metabolites. It is the metabolites that are active and irreversibly inhibit 
the ADP-dependent P2Y12 receptor of the platelets30.  
In the large randomized Clopidogrel in Unstable Angina to Prevent 
Recurrent Events (CURE) trial, DAPT with ASA + clopidogrel was 
compared to ASA only in 12,562 patients with nSTEMI ACS. The 
patients were treated over a mean length of time of 9 months. DAPT 
resulted in almost a 20% lower relative risk of the combined primary 
endpoint cardiovascular death, non-fatal myocardial infarction, or 
stroke (p < 0.001)27.  
During the study, 2,072 patients in the CURE trial (16.5%) underwent 
coronary artery bypass grafting (CABG), either at the initial 
hospitalization (49%) or later during the study period (51%). There 
was a non-significant reduction in the primary outcome in DAPT 
patients (14.5% vs. 16.2%) without any significantly higher incidence 
of major bleeding (9.6% in DAPT patients, 7.5% in placebo patients).  
Clopidogrel became a huge success, and during the last year before the 
patent expired, clopidogrel was the second-best selling drug –with 
global sales reaching $9.4 billion24. 
Figure 2. Molecular structures of different thyienopyridines used as anti-
platelet drugs. 
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1.4.3 Third generation P2Y12 inhibitors 
Despite the success of clopidogrel, patients continued to suffer 
ischaemic events, albeit to a lesser degree. Also, 15‒30% of patients did 
not respond to clopidogrel treatment31, in part due to genetic 
polymorphism of enzymes involved in hepatic metabolism32. Also, the 
relatively slow onset of clopidogrel could be problematic in acute 
settings33. 
New P2Y12 inhibitors continued to be tested in ACS patients, including 
the thienopyridine prasugrel34 and also ticagrelor35, which belongs to a 
different class of drugs (triazolpyrimidines) (Figure 3).  
Prasugrel, like clopidogrel, is a pro-drug that requires conversion to an 
active metabolite before binding irreversibly to the P2Y12 receptor. 
Compared to clopidogrel, the onset is faster, with maximal effect after 
30 minutes. This is due to a simpler metabolism, which occurs both in 
the liver and intestine. Prasugrel also has a higher and more consistent 
degree of platelet inhibition, probably related to its simpler metabolism, 
more rapid conversion to the active metabolite, and the lack of non-
responders36. 
DAPT with ASA and prasugrel was compared to DAPT with ASA and 
clopidogrel in the Trial to Assess Improvement in Therapeutic 
Outcomes by Optimizing Platelet Inhibition with Prasugrel–
Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38 involving 
13,608 ACS patients scheduled for percutaneous coronary intervention 
(PCI) treatment34. A significant reduction in the combined primary 
endpoint death from cardiovascular causes, non-fatal myocardial 
infarction (MI), or non-fatal stroke was observed (HR 0.81, 95% CI 
0.73‒0.90), but with an increased risk of bleeding complications –
including fatal bleeding. 
One of the inclusion criteria for patients in the TRITON study was a 
scheduled PCI. Despite this, 448 of 13,608 patients underwent CABG 
surgery during the study period. A sub-analysis of these patients showed 
a significant reduction in all-cause death in prasugrel-treated patients 
(HR 0.26, 95% CI 0.09‒0.77), despite there being an increased risk of 
CABG-related bleeding (13.4% vs. 3.2%; p < 0.001)37.  
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Figure 3. The molecular structure of ticagrelor. 
Ticagrelor, yet another inhibitor of the P2Y12 receptor, was introduced 
to the European market in 2010 and the US market in 2011. In contrast 
to thienopyridines, ticagrelor has a P2Y12 receptor binding site that is 
different from that of ADP, making it an allosteric antagonist, and the 
blockage is reversible38.  
Ticagrelor directly antagonizes binding of ADP to the P2Y12 receptor 
without the need for any metabolic activation, although at least one 
metabolite is active, with pharmacological characteristics similar to 
those of the parent drug. Maximum platelet inhibition is reached after 
1–3 hours of oral intake. As ticagrelor binds reversibly, individual 
platelets may regain their ability to activate through this signalling 
pathway. Recovery of platelet function is dependent on elimination of 
the drug and metabolites via hepatic metabolism. The half-life of 
ticagrelor in plasma is 6–13 hours36. 
Compared to clopidogrel, ticagrelor provides a higher degree of (and 
much less variable) P2Y12 inhibition. This is also true of prasugrel36. In 
addition to platelet inhibition, ticagrelor has other P2Y12-independent 
effects, including inhibition of cellular uptake of adenosine via the 
membrane-bound protein Equilibrative Nucleotide Transporter (ENT)-
139. This increases the circulating levels of adenosine in ticagrelor-
treated patients, which may contribute to favourable effects including 
increased coronary blood flow, improved endothelial function, and 
reduced ischaemia/reperfusion injury, and may reduce the inflammatory 
responses40.  
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In the Study of Platelet Inhibition and Patient Outcomes (PLATO) from 
2009, DAPT with ticagrelor was compared to DAPT with clopidogrel 
in 18,624 patients with ACS. Again, in patients with more potent anti-
thrombotic treatment, the outcome was superior with lower risk of the 
combined endpoint death from vascular causes, MI, or stroke35. Also, 
1,899 (10.4%) of the ACS patients included underwent CABG surgery 
during the study period. In patients who underwent CABG within 7 
days after discontinuation of study treatment, all-cause mortality was 
reduced from 9.7% to 4.7% (HR 0.49, 95% CI 0.32–0.77)41.  
1.4.4 Triple antiplatelet therapy 
One study compared the use of vorapaxar, a platelet thrombin receptor 
antagonist, in addition to standard therapy in ACS patients without 
STEMI. Standard therapy included DAPT with ASA and a 
thienopyridine in the vast majority of patients, so most patients with 
active treatment received triple antiplatelet therapy. The combined 
primary endpoint death from cardiovascular causes, myocardial 
infarction, stroke, recurrent ischaemia with re-hospitalization, or urgent 
coronary revascularization was not significantly better in patients with 
vorapaxar (HR 0.92, 95% CI 0.85–1.01), despite there being a lower 
risk of myocardial infarction (HR 0.89, 95% CI 0.81–0.98). The 
negative results were mainly due to an increased risk of bleeding, 
including haemorrhagic stroke42. 
1.5 Testing of platelet function 
Early in the twentieth century, assessment of platelet function started 
with the determination of in vivo bleeding time. The technique involves 
inflicting a small skin wound on the forearm or ear lobe and recording 
the time required for a clot to form and the bleeding to stop. This 
technique is simple and there is no need for specialized laboratory 
equipment or expertise, but the specificity of platelet function and the 
clinical significance of bleeding time have been questioned, and the 
method has been replaced by other less invasive techniques.  
During the 1950s, accurate platelet counts and description of platelet 
morphology gained wider usage. Since then, different tests have been 
developed to assess different aspects of normal platelet function, 
including tests of platelet-platelet aggregation, detection of activation-
dependent changes in the platelet surface, assessment of activation-
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dependent release from platelets, and testing of shear-induced platelet 
adhesion and aggregation43. 
Platelet function tests (PFTs) are used to diagnose both inherited and 
acquired platelet dysfunction. As the clinical use of antiplatelet drugs 
has increased, platelet function tests are also used to assess the efficacy 
of treatment. Theoretically, these tests may be used to identify both 
patients who have an increased risk of bleeding and patients with sub-
optimal drug response and high on-treatment platelet reactivity (HPR).   
Widely available viscoelastic methods (such as thromboelastography) 
that are used to test blood clotting are unable to detect the effect of 
antiplatelet medications on platelet function43.  
Aggregometry is based on the principle that blood platelets are non-
thrombogenic in their resting state, but that upon activation, surface 
receptors are exposed –enabling adhesion to sites of vascular injury, 
aggregation of platelets through interaction with fibrinogen, and 
attachment to artificial surfaces.  
Light transmission aggregometry (LTA), or turbidometric 
aggregometry, was the first laboratory test for platelet-platelet 
aggregation44. It is still regarded as the golden standard of platelet 
function testing. The test is performed using platelet-rich plasma, which 
is obtained by centrifuging anticoagulated blood. Platelet-rich plasma is 
naturally turbid and absorbs light. After addition of platelet agonists to 
the sample, the platelets aggregate and the transmission of light through 
the sample increases. The test is calibrated so that 100% corresponds to 
light levels transmitted through platelet-poor plasma. 
LTA is time-consuming and requires a specialized laboratory for 
complex sample preparation, which makes the technique unsuitable for 
many clinical situations. Point-of-care (POC) platelet function tests 
overcome these limitations and allow rapid assessment of platelet 
function. POC methods that use platelet-platelet aggregation methods 
include impedance aggregometry, VerifyNow®, and Plateletworks®.  
The multiple-electrode impedance aggregometry analyser (Multiplate®; 
Roche Diagnostics, Basel, Switzerland) uses whole-blood samples. 
Sample and platelet-stimulating reagent are added to test cells, which 
incorporates two sets of paired sensor wires and a coated stirring 
magnet. Platelets adhere to the sensor wires and increase the electrical 
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resistance between them. The increase in impedance is measured in 
aggregation units (AU) and plotted against time. The area under the 
curve (AUC) is a measure of platelet aggregation, and measured in (AU 
× min), which is then converted to units (U) for simplicity (Figure 4).  
 
Figure 4. Principles of Multiplate® platelet aggregation testing. Platelets are 
shown in the blood samples with an electrode pair (top left). After addition of 
an agonist (top middle), platelets are activated and aggregate at the electrodes 
(top right). The aggregation of platelets increases the electrical resistance 
between electrodes. Two electrode pairs continuously record two seperate 
aggregation curves (bottom). The average aggregation curve is used to calculate 
the area under the curve (AUC) wich is an estimate of platelet reactivity. 
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Several specific tests are available for stimulation of different receptors 
or signal transduction pathways, including: 
• ASPI test: arachidonic acid (AA) is added for formation 
of the potent platelet agonist thromboxane A2 via the 
COX enzyme. If the COX enzyme is inactivated (i.e. by 
ASA or anti-inflammatory drugs) platelets will not be 
activated. 
• ADP test: ADP activates platelets by stimulation of 
platelet ADP receptors, including the P2Y12 receptor. 
• TRAP test: thrombin receptor-activating peptide-6 
stimulates the thrombin receptors PAR-1 and PAR-4 on 
the platelet surface. This signalling is not blocked by 
ASA or P2Y12 inhibitors, thus allowing TRAP tests to 
detect the effect of GpIIb/IIIa receptor inhibitors in 
blood samples from patients treated with ASA or P2Y12 
inhibitors. 
Impedance aggregometry may predict stent thrombosis and bleeding 
after PCI treatment45 46, platelet transfusion in adult cardiac surgery 
patients47, and postoperative bleeding in patients undergoing cardiac 
surgery with preoperative thienopyridine treatment48. 
1.6 Cardiac surgery 
Surgery on the heart was first described in case reports of traumatic 
stab wounds. The first successful repair is attributed to Dr Ludwig 
Rehn of Frankfurt, Germany. In 1896, a 22-year-old patient suffered a 
penetrating trauma to the right ventricle and presented with severe 
shock. During surgery, a 1.5-cm stab wound was identified on the right 
ventricle and three sutures were placed. Full recovery followed, and Dr 
Rehn concluded his remarks with the following: “I hope this will lead 
to more investigation regarding surgery of the heart. This may save 
many lives.”49 
After the combined efforts of the medical and engineering professions, 
the first successful operation with the aid of a heart-lung machine was 
performed by John Gibbon on 6 May 1953, on an 18-year-old woman 
with heart failure due to atrial septal defect50. Dismayed by subsequent 
failed operations, largely due to imprecise preoperative diagnoses, 
Gibbon soon stopped performing cardiac operations, but other 
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surgeons continued to refine the heart-lung machine and to use it to 
operate on patients with various cardiac pathologies. 
With increasing insight that ischaemic heart disease and angina pectoris 
were conditions associated with reduced myocardial blood flow, novel 
methods were developed to restore myocardial perfusion. Claude Beck, 
a Cleveland surgeon, developed methods to restore blood flow to 
animal hearts by attaching adjacent tissue, such as pectoral muscles and 
the omentum. He also experimented with grafting of the internal 
mammary artery to the coronary venous system51. Implantation of the 
internal mammary artery into a tunnel of ischaemic left ventricle 
myocardium was performed in several cases by the Canadian surgeon 
Arthur Vineberg52. After the development of angiography, patent grafts 
were amazingly demonstrated with communications to the coronary 
system, and case reports have demonstrated patent grafts up to 30 years 
after surgery53.  
With the advent of coronary angiography, it became possible to plan 
coronary grafting and assess the results postoperatively54. 
Endarterectomy and patching of coronary arteries with pericardium or 
saphenous veins were tested, and sporadic cases of aorto-coronary 
grafting were reported during the 1960s as an alternative or bail-out 
method after difficulties with these procedures. It was Favaloro and 
Effler at the Cleveland Clinic who developed the CABG operation 
similar to what is used today55. They performed their first operation 
using saphenous vein graft conduit in 1967. Three years later, the 
internal mammary artery was being used to graft the left anterior 
descending artery (Figure 5).  
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Figure 5. Coronary artery bypass grafting with internal mammary artery and 
saphenous vein grafts. Illustration by Patrick J. Lynch, medical illustrator; C. 
Carl Jaffe, MD, cardiologist. 
Preoperative diagnostics, surgical techniques, perioperative care, and 
pharmacological treatments have evolved during the last five decades51, 
with improved survival and lower complication rates –despite the fact 
that the patients’ age and risk factors have increased in recent years56.  
1.6.1 Bleeding after cardiac surgery 
All open-heart surgery is associated with some degree of perioperative 
bleeding, due to both surgical trauma and impaired haemostasis. 
Several factors are associated with impaired haemostasis, including the 
preoperative use of antithrombotic drugs57, haemodilution caused by 
prime volume in the cardiopulmonary bypass (CPB) circuit58, reduced 
platelet count and dysfunction after CPB, enhanced fibirinolysis, and 
hypothermia during surgery59. 
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Excessive bleeding is widely recognized as being a risk factor after 
cardiac surgery60 61. This has been reported using a number of different 
variables, including postoperative chest-tube output62, transfusion of 
blood products63, and re-operation for bleeding or tamponade64.  
In addition to using a single variable to estimate bleeding, a number of 
clinical studies have defined composite endpoints, as exemplified in 
Table 1. Although definitions for many other complications after 
cardiac surgery exist65, no standardized definition of perioperative 
bleeding has been established, making the interpretation and 
comparison of clinical trials more difficult.  
Of these composite endpoints, only the UDPB class has been externally 
evaluated for prediction of mortality65. Using a single-centre cohort of 
1,144 adult patients, mortality was assessed after adjusting for other 
relevant risk factors. Bleeding class remained an independent predictor 
of 30-day mortality, with an eightfold increase in risk in patients with 
severe bleeding compared to patients with insignificant bleeding. 
BART66 BARC67 PLATO CABG35 UDPB65 
CTO > 1.5 liter 
(any 8-h period) 
 
> 10 RBCs/24 h 
 
 
Re-operation 
for bleeding 
 
Fatal bleeding 
CTO ≥ 2 L/24 h  
 
 
≥ 5 U whole 
blood/RBCs/48 h 
 
Re-operation for 
bleeding 
 
Intracranial 
bleeding  
Drop in Hb ≥ 5.0 
g/dL 
 
≥ 4 RBCs 
 
 
Re-operation for 
bleeding 
 
Fatal bleeding 
CTO > 1 L/12 h 
 
 
≥ 5 RBCs/24 h 
≥ 5 FFP/24 h 
 
Re-operation 
for bleeding 
 
Delayed sternal 
closure 
 
Use of rFVIIa 
Table 1. Definitions of major bleeding. CTO = chest tube output; Hb = 
haemoglobin RBC = red blood cell; FFP = fresh frozen plasma; rVIIa = 
recombinant activated factor VII (NovoSeven®). 
1.7 Preoperative APT and risk of bleeding 
Patients undergoing cardiac surgery with ongoing or recently 
discontinued DAPT have an increased risk of bleeding68, which is 
associated with poor clinical outcome65. Despite the risk of bleeding, 
patients with ongoing ischaemia or haemodynamic instability should be 
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operated without delay, regardless of the discontinuation time of the 
DAPT69.  
In stable patients, P2Y12 inhibitors should be discontinued for an 
adequately long period to allow recovery of platelet function. Current 
guidelines recommend five days for clopidogrel, seven days for 
prasugrel, and five days for ticagrelor69 70. These recommendations are 
based on the pharmacological properties of the P2Y12 inhibitors36, the 
recovery of platelet function after drug discontinuation in patients with 
stable angina71, and experience from CABG subgroups in randomized 
trials37 41 72. A nationwide Swedish study showed that discontinuation of 
the platelet inhibitor three days before surgery, as opposed to five days, 
did not increase the incidence of major bleeding complications in 
ticagrelor-treated patients undergoing CABG73, supporting the 
implementation of a shorter discontinuation time in these patients.   
In semi-elective and urgent cases with increased risk of thrombosis (i.e. 
patients with critical coronary anatomy or previous recurrent episodes 
of ischaemia), case-by-case decisions should be made to balance the risk 
of thrombosis and the risk of bleeding. There are no clear 
recommendations on how to assess the risk of recurrent ischaemia in 
the stabilized patient with an ACS, although discontinuation of P2Y12 
inhibitor treatment might be associated with an increased risk of death 
and myocardial infarction74.  
Time since discontinuation may be used to assess bleeding risk, but 
there is individual variation in the magnitude and duration of the anti-
platelet effect of P2Y12 inhibitors36 71. An individualized assessment 
based on platelet function shortly before operation might therefore be 
preferable to the discontinuation time for prediction of the risk of 
bleeding complications. This approach is endorsed in the European re-
vascularization guidelines, which state that platelet function testing 
should be used to guide interruption of antiplatelet therapy, rather than 
using an arbitrary specified period of delay in patients undergoing 
CABG surgery69. However, this statement is based on limited data75 76, 
as indicated by a C level of evidence. Evidence in support of this 
approach has so far been published only for thienopyridine-treated 
CABG patients48 77, with no data being available for patients treated 
with the newer and more efficient platelet inhibitor ticagrelor. 
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1.8 Antiplatelet therapy after CABG surgery 
Excessive bleeding –not thromboembolic complications– has been the 
major haemostatic concern during the early postoperative period. 
However, thrombotic complications are not uncommon after cardiac 
surgery and may, at least in part, be avoided with optimal perioperative 
care78. 
Early restart of ASA after CABG surgery is associated with reduced 30-
day mortality and ischaemic complications of the heart, brain, kidneys, 
and intestines79. During the first postoperative year, vein graft patency 
is improved80. Today, low-dose ASA is recommended and used in the 
absence of contraindications in nearly all CABG patients69 81. 
Whether more intense antiplatelet therapy, such as DAPT, benefits the 
subset of ACS patients who undergo CABG surgery (approximately 
10%82) has not been adequately studied, but a number of indications 
support the hypothesis. For instance, platelet and coagulation systems 
are activated in ACS patients83; ACS patients often have multiple 
vulnerable coronary artery plaques in addition to the culprit lesion84; 
and vein graft conduits are at risk of failure through thrombosis, 
intimal hyperplasia, and accelerated atherosclerosis85, associated with 
worse outcome86.  
There have been no large randomized controlled trials, but two meta-
analyses have reported the outcome when intensified antiplatelet 
therapy was used after CABG. The first meta-analysis included a total 
of 25,728 patients from both randomized and observational studies87 
comparing DAPT with ASA + clopidogrel to single therapy with only 
ASA. DAPT was associated with better early vein graft patency (RR 
0.59, 95% CI 0.43–0.82; p = 0.02) and also lower 30-day mortality 
(0.8% vs. 1.9%; p < 0.0001). Long-term survival was not reported.  
The second meta-analysis studied the effect of intensified antiplatelet 
therapy after CABG, using somewhat overlapping data compared to the 
previous meta-analysis. Altogether, 4,829 patients from (1) five 
randomized controlled trials on elective CABG patients (a total of 979 
patients) and (2) four sub-studies of CABG-treated patients from large 
randomized controlled trials (RCTs) of ACS (a total of 3,850 patients) 
were included in the meta-analysis. In patients with more intense 
antiplatelet therapy, there was a trend of lower all-cause mortality (RR 
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0.68, 95% CI 0.43‒1.08), despite an increased risk of major bleeding 
(RR 1.31, 95% CI 0.81‒2.10)88. 
One additional study, not included in either of the meta-analyses, 
compared DAPT with ASA + ticagrelor to ASA only during the first 3 
months after isolated CABG89. Primary outcome was graft occlusion on 
CT angiography (CTA), performed three months after surgery. The 
study was underpowered, due to premature termination because of slow 
recruitment. Nevertheless, due to larger benefit than expected on graft 
patency, ticagrelor treatment was associated with a significant reduction 
in graft occlusion (7/25 patients vs. 17/31; p = 0.044). The study was 
not powered to compare clinical endpoints of cardiovascular or 
bleeding events. 
Current guidelines recommend starting DAPT for ACS patients 
undergoing CABG “as soon as considered safe” after surgery, with a 
recommended duration of 12 months (class 2A, level C 
recommendation)69 90. The reported adherence to the recommendation 
has been low, with the use of DAPT in only 20–45% of patients after 
CABG91-93.  
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1.9 Fibrinolysis and cardiac surgery 
The use of CPB results in increased plasma levels of tPA94, with 
subsequent generation of plasmin59 and increased fibrinolysis.   
 
Figure 6. The chemical structure of lysine (top left), epsilon amino caproic acid 
(top middle), and tranexamic acid (top right). The 58 amino acids of the more 
complex polypeptide aprotininl are also shown (bottom). The inhibition of 
plasmin is associated with the 15th amino acid lysine (highlighted in red), which 
acts as a binding site for most of the serine proteases that it inhibits. 
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The antifibrinolytic drugs tranexamic acid (TA), epsilon amino caproic 
acid (EACA), and aprotinin can reduce hyper-fibrinolysis. TA and 
EACA are small molecules with structures similar to lysine, while 
aprotinin is a more complex molecule consisting of 58 amino acids 
(Figure 6). TA, EACA, and aprotinin (through a lysine amino acid) all 
bind to the lysine-binding site of plasmin, thereby hindering the 
association and subsequent degradation of fibrin (Figure 7).  
Aprotinin has additional biological effects by inhibition of other serine 
proteases95. It has also been reported that aprotinin improves platelet 
function in different settings, including the restoration of platelet 
function deficits induced by long-term storage or CPB96, attenuation of 
eptifibatide-induced platelet inhibition97, and improvement of the ADP-
dependent platelet activation in CABG surgery patients98.  
 
Figure 7. The mechanism of normal fibrinolysis (left) and inhibition with anti-
fibrinolytic drug (right). P = plasminogen; PA = plasminogen activator; L = 
lysine analogue. 
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The use of antifibrinolytic drugs in cardiac surgery dates back to the 
early 1960s99. In 1989, a placebo-controlled study on a series of 350 
patients found that prophylactic use of EACA decreased postoperative 
chest-tube drainage and transfusion without increasing thrombotic 
complications100. Since then, there have been other, similar reports101. 
Of the three antifibrinolytic drugs, aprotinin has the strongest effect on 
blood loss and transfusions102.  
The routine use of antifibrinolytics is debated, especially in low-risk 
patients103 104. Despite aprotinin’s greater ability to reduce blood loss, a 
large, randomized controlled trial comparing the three drugs was 
terminated early because of an increase in mortality in those treated 
with aprotinin66. This led to the withdrawal of aprotinin from the 
market in 2008. Later reviews revealed problems with the BART  
study105 106, and in Europe and Canada, the suspension of aprotinin was 
subsequently lifted for CABG patients.  
Today, it is unclear which cardiac surgery patients would benefit from 
aprotinin treatment, but patients with ongoing or recently stopped 
DAPT are one possible subgroup. 
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2 AIM 
The goal of this project was to increase the understanding of how 
patients with antiplatelet therapy considered for CABG are best 
managed, and also investigate if different postoperative antiplatelet 
treatment strategies affect postoperative survival after CABG in ACS 
patients.   
Seven specific aims have been defined: 
1. To describe the recovery of platelet function after 
withdrawal of dual antiplatelet therapy with ASA and 
ticagrelor treatment in patients with ACS (paper I) 
2. To investigate the efficacy of platelet transfusion at 
consecutive time points after withdrawal of ticagrelor in 
patients with ACS (paper I) 
3. To investigate if preoperative PFT using impedance 
aggregometry can predict the risk for bleeding 
complications in patients with recently discontinued 
ticagrelor treatment (paper II) 
4. To investigate if aprotinin or tranexamic acid improves 
platelet function in patients with ongoing DAPT with 
ticagrelor and ASA (paper III) 
5. To describe the prevalence of DAPT in ACS patients 
after CABG in Sweden (paper IV) 
6. To investigate if there is a difference in one-year all-
cause mortality in patients with ACS undergoing CABG 
discharged with DAPT using ASA and clopidogrel or 
ticagrelor compared to ASA alone (paper IV) 
7. To investigate if there is a difference in one-year all-
cause mortality in patients with ACS undergoing CABG 
discharged with DAPT using ASA and ticagrelor 
compared to ASA alone (paper IV) 
  
Cardiac surgery and antiplatelet therapy 
24 
 
Carl Johan Malm 
25 
3 PATIENTS AND METHODS 
3.1 Patients 
All studies were conducted in accordance with the Declaration of 
Helsinki, and were approved by the regional ethics review board at the 
University of Gothenburg. The ethics review board waived the need for 
informed consent in study II and study IV. In study I and III the patients 
were included after obtaining written informed consent. 
All patients in the studies were hospitalized for ACS. In papers I, II and 
IV, all patients underwent cardiac surgery as treatment for the ACS, 
while patients in study III had different treatment strategies including 
medical, percutaneous coronary intervention (PCI), and surgery. Patient 
characteristics are summarized in Table 2. 
 Paper I Paper II Paper III Paper IV 
n 25 90 30 5183 
Age (years) 68 ± 9 68 ± 9 65 ± 9 67 ± 9 
Female gender 2 (8%) 18 (20%) 4 (20%) 1061 (20%) 
Study period 
Jan 2013 – 
May 2015 
Oct 2012 – 
Apr 2015 
Mar 2014 – 
Mar 2016 
Jan 2012 – 
Dec 2015 
Hb (g/L) 139 ±14 137 ± 15 142 ± 3 137 ± 15 
PLT (x109/L) 236 ± 63 246 ± 64 271 ± 26 NA 
s-Cr (μmol/L) 92 ± 18 92 ± 32 92 ± 6.8 91 ± 56 
Diabetes 3 (12%) 25 (28%) 8 (27%) 1415 (27%) 
ASA + 
clopidogrel 
0 0 0 447 (9%)* 
ASA + 
ticagrelor 
25 (100%) 90 (100%) 30 (100%) 896 (17%)* 
Table 2. Patient characteristics. Number with percentage or mean ± SD; 
Hb = Haemoglobinb; PLT = Platelet count; s-Cr = Serum-creatinine; 
ASA = Acetylsalicylic acid; * treatment at discharge 
3.2 Methods 
3.2.1 Dual antiplatelet therapy 
Patients with DAPT were studied in all four papers. In papers I, II and 
III, only patients with DAPT using ASA and ticagrelor were included. In 
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paper IV, patients treated with both ASA and ticagrelor and ASA and 
clopidogrel were included. 
3.2.2 Platelet function testing 
Multi-electrode impedance aggregometry (MEA; Multiplate®; Roche 
Diagnostics, Basel, Switzerland) was used to test platelet function in 
papers I, II and III. Blood was sampled from peripheral veins and 
collected in test tubes with hirudin anticoagulation. Three different tests 
were used to activate platelets: the ADP-HS (high sensitivity) test, which 
uses ADP in combination with prostaglandin E1 to assess P2Y12-
dependent aggregation (papers I, II, III), the ASPI test (papers I, II, III) 
and the TRAP test (papers I, II). 
The manufacturer’s normal range when using hirudin anticoagulated 
blood is 43–100 U for the ADP-HS test, 71–115 U for the ASPI test and 
84–128 U for the TRAP test. If the difference between the two electrode 
pairs was greater than 20% the analysis was considered flawed and 
repeated. 
3.2.3 Platelet supplementation 
Ex vivo supplementation with platelets was done in study I and III using 
ABO-compatible apheresis platelets from the local blood bank. 
Supplemented doses were adjusted to correspond to clinical relevant in 
vivo doses (2–4 units of apheresis platelets transfused to a 70 kg 
patient).  
3.2.4 Paper I 
Paper I is divided in two sub-studies. In sub-study I the recovery of 
platelet function was studied in 25 ACS patients with DAPT awaiting 
CABG surgery. Ticagrelor treatment was stopped upon acceptance for 
CABG, and MEA was subsequently done at five time points: after 12, 
24, 48, 72 and 96 hours.  
In sub-study II, samples from 15 of the 25 patients were supplemented 
with either a low or high dose of platelet concentrates corresponding to 
2 or 4 units of transfused apheresis platelets. Platelet supplementation 
and testing was performed at the same time points as in sub-study I.  
Carl Johan Malm 
27 
3.2.5 Paper II 
Ninety ACS patients with DAPT requiring acute or urgent cardiac 
surgery were included in a prospective observational study. All patients 
had ongoing or recently (< 5 days) discontinued ticagrelor treatment 
and ongoing ASA treatment at the time of surgery. The decision to 
operate despite the ticagrelor discontinuation time being shorter than 
recommended was made by a heart team, including a senior cardiac 
surgeon, the treating cardiologist and a and a senior cardiac 
interventionist.  
Blood samples were collected immediately before surgery and analysed 
with MEA using ADP-HS, ASPI and TRAP tests. Operative data, chest 
tube output, incidence of re-exploration for bleeding, transfusion of 
blood products and the use of pro-haemostatic drugs was collected 
from hospital records. Severe bleeding according to UDPB criteria (one 
or more of the following: chest tube output > 1 L during the first 12 
hours; transfusion of ≥ 5 units of red blood cells or ≥ 5 units of fresh 
frozen plasm during the first 24 hours; re-operation for bleeding within 
24 hours; delayed sternal closure; or use of recombinant factor VII) was 
compared for different preoperative values of the aggregation tests, and 
the accuracy for predicting severe bleeding was explored using receiver 
operating characteristic (ROC) curves. 
3.2.6 Paper III 
Blood samples were obtained from 30 patients hospitalized due to ACS. 
All patients had ongoing DAPT and had received at least two 90 mg 
doses of ticagrelor at the time of blood sampling. 
Each sample was divided in five portions. First, a portion for baseline 
platelet function was secured. Two portions were supplemented with 
either a low or high dose of aprotinin, corresponding to the clinical use 
of half or full Hammersmith regimen107. The last two portions were 
supplemented with different doses of TA, corresponding to intravenous 
bolus doses of either 1 g or 2 g. ADP- and AA-induced aggregation was 
assessed for all portions. 
In a subset of 20 patients, a part of each portion was also supplemented 
with platelet concentrates corresponding to 3 units of transfused 
apheresis platelets, after which the same analyses were performed. 
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3.2.7 Paper IV 
Data from the SWEDEHEART registry was collected for all patients 
undergoing isolated CABG surgery in Sweden during 2012 – 2015. 
Data included > 100 patient variables such as preoperative risk factors, 
operative variables, postoperative complications, and medications at 
discharge. Due to incomplete data of medications at discharge from 
four centres (Karlskrona, Lund, Umeå, Örebro) manual retrieval of this 
information was done from hospital records.    
6,020 patients with ACS undergoing isolated CABG was identified 
during the study period. Patients with in-hospital mortality, patients 
discharged with anticoagulation or rare combinations of antiplatelet 
therapy and foreign patients without mortality follow-up data were 
excluded. Thirteen patients underwent two isolated CABG procedures 
during the study period, and their first procedure was excluded from 
the analysis. The remaining 5,183 patients were divided in three groups 
according to their antiplatelet medication at discharge: ASA only 
(n=3,840), DAPT using ASA and clopidogrel (n=447), and DAPT using 
ASA and ticagrelor (n=896) (Figure 8).    
Figure 8. Flow chart for paper IV. 
Mortality data during the first year after surgery was derived from the 
Swedish national population registry, which is 100% complete 
(excluding 45 patients that were not Swedish citizens). Mortality was 
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then compared between the different treatment groups using both crude 
and propensity score matched data. 
3.3 Statistical analyses 
For all studies, the data was presented as mean with standard deviation 
(SD), mean with standard error of the mean (SEM), median with range 
or interquartile range (IQR), or frequency with percent. Normality of 
data was tested with the Shapiro–Wilk test (papers I – III). Statistical 
significance was assumed when the two-sided p-value was < 0.05. 
All statistical analyses were made with computer software (IBM SPSS 
Statistics software ver. 22 – 23, IBM Corp. Armonk, NY, USA; Prism 
6.0, GraphPad Software Inc., La Jolla, CA, USA; SAS Software version 
9.4, SAS institute, Cary, NC, USA; R software, version 3.0.3, 
http://www.R-project.org/; and Stata 13, StataCorp, College Station, 
TX, USA) 
3.3.1 Paper I 
Sub-study I was regarded as a descriptive pilot study. For sub-study II, 
15 pairs of samples gave 80% power with a two-sided test to detect a 
difference of 10 U in ADP-induced platelet aggregation when platelet 
concentrate was added, at α=0.05 and a standard deviation of 12 U.  
Change in platelet aggregation over time compared with baseline was 
tested with a general linear model for repeated measurements. A mixed 
effects model for repeated measurements was used to analyse efficacy of 
platelet concentrate addition and interaction between time point and 
dose of platelets. No formal adjustment for multiplicity was assumed 
necessary.  
3.3.2 Paper II 
Categorical variables were compared using Fisher’s exact test. 
Continuous variables were compared with Student’s unpaired t-test 
(normally distributed data) or the Mann–Whitney U-test (non-
parametric data).  
The accuracy of aggregability tests for predicting severe bleeding was 
explored using a receiver operating characteristic (ROC) curve, which 
yielded an area under the curve (AUC) with its accompanying 95% CI. 
Youden’s index, J = (sensitivity + specificity − 1), was defined for all 
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points on the ROC curve. The maximal Youden’s index value was used 
as a criterion for selecting the optimal cut-off point. 
Positive predictive value (PPV) and negative predictive value (NPV) 
were calculated according to standard methods. The association 
between the preoperative ADP HS test value and the probability of 
severe bleeding was explored with logistic regression analysis.  
3.3.3 Paper III 
Twenty pairs of samples gave a power of 84% with a 2-sided test to 
detect a difference of 25% in ADP-induced platelet aggregation 
(baseline aggregation=13 U), at α=0.05 and a standard deviation of 3.5. 
The aggregometry results after addition of different supplements were 
compared to baseline results using Student’s paired t-test.  
3.3.4 Paper IV 
All-cause mortality was compared with univariable and multivariable 
Cox proportional hazards regression models applied to unmatched and 
propensity score (PS) matched data. The PS matching was based on a 
27 pre- and perioperative covariates and performed separately for each 
pairwise comparisons. The covariates included 18 variables used in 
Euroscore II risk model108. Data imputation was performed for two of 
these variables, postoperative circulatory support and pulmonary 
hypertension, where “0” was imputed when data were missing. In 
addition, preoperative haemoglobin, type of acute coronary syndrome 
(UA, nSTEMI or STEMI) and the following postoperative 
complications were included as covariates:  postoperative circulatory 
support, new dialysis, new stroke, reoperation for bleeding, reoperation 
for mediastinitis, prolonged mechanical ventilation (> 48 h), and 
postoperative atrial fibrillation. 
The PS matching was performed with the MatchIt package in R 3.03. 
Greedy matching method was used with up to three control patients 
matched to each treated patient and a calliper of 0.2 (i.e. the difference 
in PS between two matched patients is at most 0.2 SD of the PS)109. 
Ten variables were included in the multivariable Cox proportional 
hazard regression analysis: antiplatelet treatment, log Euroscore II, type 
of ACS, postoperative circulatory support, new dialysis, new stroke, 
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reoperation for bleeding, reoperation for mediastinitis, prolonged 
mechanical ventilation (> 48 h), and new atrial fibrillation.   
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4 RESULTS 
4.1 Platelet function after ticagrelor 
discontinuation 
In the first sub-study of paper I, mean ADP-induced platelet aggregation 
increased gradually after the discontinuation of ticagrelor treatment. 
After 96 hours, the mean level of aggregation was 55 ± 31 U compared 
to 10 ± 8 U at 12 hours after discontinuation (p < 0.001, Figure 9 A). 
There was a high degree of inter-individual variability in recovery of 
platelet function (Figure 9 B). AA- and TRAP-induced platelet 
aggregation also increased significantly with time, albeit to lesser extent 
(Figure 9 A).  
 
Figure 9. A. Mean ADP-, AA- and TRAP-induced platelet aggregation at 
consecutive sampling time points after ticagrelor discontinuation. B. ADP-
induced aggregation of individual patients at consecutive sampling time points 
after ticagrelor discontinuation. 
In paper II, there was a weak linear correlation between the time since 
last dose of ticagrelor and ADP-induced platelet aggregation (R2=0.30, 
P<0.001). Individual aggregation values had a wide spread around the 
linear regression line (Figure 10 B). 
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Figure 10. A. Preoperative ADP-induced aggregation grouped in five intervals 
of different discontinuation times. B. Scatter plot of ADP-induced aggregation 
and time after discontinuation of ticagrelor. There was a weak linear 
correlation between the plotted variables (R2=0.30, P<0.001). 
 
4.2 Platelet supplementation after ticagrelor 
discontinuation 
In the second sub-study of paper I, supplementation with low or high 
dose of platelet concentrate did not increase the ADP-induced platelet 
aggregation at any time point (Figure 11 A). In contrast, AA-induced 
aggregation was markedly increased at all time points after 
supplementation using the low dose of platelets (p<0.001), with an even 
higher increase using the higher dose (+21 U, p = 0.0013) (Figure 11 B). 
TRAP-induced platelet aggregation was significantly increased after 
addition of the higher dose of platelet concentrate (11 U; p=0.0058), 
but not with the lower dose (p=0.59) (Figure 11 C). 
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Figure 11. Mean platelet aggregation at consecutive time points after ticagrelor 
discontinuation at baseline and after supplementation of low and high dose 
platelet concentrate. A. ADP-induced platelet aggregation. B. AA-induced 
platelet aggregation. C. TRAP-induced platelet aggregation. Whiskers denote 
upper standard deviation. 
 
4.3 Risk of bleeding in ticagrelor-treated 
patients 
In paper II, the median time between last dose of ticagrelor and start of 
surgery was 35 h (4-108 h). Thirty-two of 90 (36 %) patients suffered 
severe bleeding according to the UDPB criteria.  
Patients with severe bleeding had a lower median preoperative ADP-
induced platelet aggregation compared with non-bleeders (17 vs 32 U, p 
< 0.001), but no significant difference in AA- and TRAP-induced 
aggregation.  
The accuracy of platelet function tests to predict severe bleeding was 
highest for the ADP-HS test, with an area under the ROC curve of 0.73 
(95% CI 0.63–0.84). Corresponding values for the TRAP- and ASPI-
tests were significantly lower (TRAP 0.61, 95% CI 0.49–0.74; ASPI 
0.53, 95% CI 0.40–0.66).  
The maximal Youden’s index for ADP-induced aggregation was 22 U. 
Using this cut-off value, the sensitivity was 75% and specificity 76% in 
our cohort. Patients with an ADP-test below the cut-off (<22 U) had 
greater median postoperative bleeding volume (660 vs 470 ml, p = 
0.004), higher incidence of re-exploration for bleeding (16 vs 4 %, p = 
0.066), and were more likely to receive transfusions of RBCs (76 vs 58 
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%, p = 0.076), plasma (66 vs 21 %, p < 0.001), and platelets (76 vs 
27%, p < 0.001). The distribution of the patients preoperative ADP-
induced aggregation and the individual values of patients with severe 
bleeding is shown in Figure 12.  
 
Figure 12. The distribution of the ADP- induced aggregation values. The upper 
portion of the figure shows a scatter plot of the ADP-induced aggregation of 
the subjects with severe bleeding. The normal range of ADP-induced 
aggregation (43–100 U) is marked by a green background. 
 
Median closure time (time from weaning off CPB to skin closure) was 
88 min in subjects with ADP-induced aggregation < 22 U, compared 
with 52 min in subjects with ADP ≥ 22 U (p < 0.001). Using univariable 
logistic regression analysis, a model was fitted to predict the risk for 
severe bleeding complications depending on the preoperative ADP-
induced aggregation. Low preoperative ADP-induced aggregation was 
associated with a markedly increased risk of bleeding (Figure 13). 
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Figure 13. The probability of severe bleeding in relation to the preoperative 
ADP-induced aggregation. The grey area corresponds to the 95% confidence 
interval. 
 
4.4 Influence of aprotinin or tranexamic acid on 
platelet function  
In paper III, the addition of aprotinin increased the ADP-induced 
aggregation compared to baseline levels in whole blood samples from 
ACS patients with ongoing ASA and ticagrelor treatment. Low dose 
aprotinin increase aggregation with 20.4 ± 6.0 % (p = 0.004), and high 
dose increase with 22.6 ± 5.4 % (p < 0.001). The addition of TA did 
not alter ADP-induced aggregation (low dose +3.2 ± 7.5 %, p = 0.55; 
high dose −5.3 ± 6.3 %, p = 0.50) (Figure 14). 
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Figure 14. Changes from baseline in ADP-dependent platelet aggregation after 
addition of low or high dose aprotinin and tranexamic acid. Apr = aprotinin; 
TA = tranexamic acid. 
 
Similar to the results from paper I, the addition of platelets did not 
significantly change ADP-induced aggregation (+11.8 ± 5.0 %, p = 
0.12). The addition of both platelets and aprotinin increased ADP-
induced aggregation from baseline to a similar degree as when only 
aprotinin was used: platelets and low dose aprotinin +23.5 ± 7.3 % (p = 
0.003); platelets and high dose aprotinin +26.0 ± 9.4 % (p = 0.016).  
The combination of TA and platelets did not have any effect on ADP-
induced aggregation (low dose +8.6 ± 7.6 %, p = 0.41; high dose +1.6 ± 
5.3 %, p = 0.79). 
AA-induced aggregation did not significantly change after addition of 
aprotinin compared to baseline (low dose +44.6 ± 22.4 %, p = 0.066; 
high dose +30.2 ± 17.5 %, p = 0.32). The addition of TA slightly 
decreased AA-induced aggregation compared to baseline in both low 
dose (−4.7 ± 12.6 %, p = 0.010) and high dose (−18.6 ± 10.3 %, p = 
0.002). 
In line with the results in paper I, the addition of platelets, alone or in 
combination with either antifibrinolytic agent markedly increased AA-
induced aggregation compared to baseline (figure 15). 
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Figure 15. Changes from baseline in AA-dependent platelet aggregation after 
addition of platelets in combination with low or high dose aprotinin or in 
combination with low or high dose TA. Plts = platelets; Apr = aprotinin; TA = 
tranexamic acid. 
 
4.5 Prevalence of DAPT after CABG surgery 
After exclusion of patients with anticoagulation, the antiplatelet 
treatment at discharge was only ASA in the majority of cases (n = 
3,840, 72.2%). Any combination of DAPT was used in 25.4%. The 
proportion of patients discharged with ASA and ticagrelor increased 
from 3.6% in 2012 to 24% in 2015, while the use of ASA and 
clopidogrel decreased from 13% to 4.7% during the study period 
(Figure 16). 
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Figure 16. Proportion of ACS patients treated with different antiplatelet 
therapies at discharge after CABG. 
 
 
4.6 Antiplatelet therapy and mortality after 
CABG surgery 
Unadjusted mortality one year after discharge differed between the 
antiplatelet treatment groups:  ASA only: 107 / 3840 (2.8 %); ASA and 
clopidogrel: 13 / 447 (2.9 %); ASA and ticagrelor: 8 / 896 (0.9 %) (p = 
0.004). 
DAPT with clopidogrel was not associated with increased survival 
compared to ASA only using either unadjusted (HR = 1.02, p = 0.95) or 
PS matched data (HR = 0.79, p = 0.49). ASA + ticagrelor was 
associated with reduced mortality in both the unadjusted (HR = 0.34, p 
= 0.002) and PS matched analysis (HR = 0.42 p = 0.020) (figure 17). 
Combining clopidogrel and ticagrelor patients in one group, data 
indicated a survival benefit of more intense antiplatelet therapy 
(unadjusted data: HR = 0.58, p = 0.02; PS matched data: HR = 0.54, p 
= 0.012). 
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Figure 17. All-cause mortality after discharge in CABG treated ACS patients of 
propensity score matched groups.  ASA = Acetylsalicylic acid; Tic. = ticagrelor. 
 
Hazard ratios were calculated using multivariable Cox regression for 
both unmatched and PS matched groups. There was a general 
agreement between the univariable and multivariable regression 
analyses (Table 3). 
  
Cardiac surgery and antiplatelet therapy 
42 
 Univariable Cox regr. Multivariable Cox regr. 
Unmatched 
groups 
PS matched 
groups 
Unmatched 
groups 
PS matched 
groups 
DAPT vs  
ASA 
0.58 
(0.36-0.92) 
0.54 
(0.33-0.88) 
0.57 
(0.36-0.92) 
0.51 
(0.31-0.85) 
Clop. + ASA 
vs ASA 
1.02 
(0.57-1.81) 
0.79 
(0.41-1.53) 
0.91 
(0.51-1.62) 
0.76 
(0.39-1.49) 
Tic. + ASA vs 
ASA 
0.34 
(0.17-0.70) 
0.42 
(0.20-0.89) 
0.35 
(0.17-0.73) 
0.45 
(0.21-0.97) 
Tic. + ASA vs 
clop. + ASA 
0.33 
(0.14-0.80) 
0.39 
(0.16-0.98) 
0.39 
(0.16-0.98) 
0.41 
(0.16-1.04) 
Table 3. Hazard ratios for comparisons of different postoperative 
antiplatelet treatments calculated with univariable and multivariable 
Cox regression analysis for both unmatched and propensity score 
matched groups of patients. 95% confidence intervals are given within 
parenthesis. PS = propensity score; DAPT = dual antiplatelet therapy; 
ASA = acetylsalicylic acid; Clop. = clopidogrel; Tic. = ticagrelor 
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5 DISCUSSION 
Guidelines recommend that a multi-disciplinary heart team involving 
both surgeons and cardiologists should discuss ACS patients in need of 
cardiac surgery69.  Among other factors, two opposing risks should be 
considered in the ACS patient. First, there is the risk of additional 
ischaemic events. This risk is increased early after the initial event, and 
may be linked to thrombotic events at both culprit and non-culprit 
lesions110. Patients considered for CABG may be particularly 
susceptible, as they usually have a high atherosclerotic burden and more 
advanced coronary artery disease. Other contributory risk factors 
include a pro-coagulant and pro-inflammatory milieu associated with 
an acute myocardial infarction111 and, if patients have recently 
undergone PCI treatment, the risk of early stent thrombosis112.  
Secondly, one should consider the risk of perioperative bleeding. Severe 
bleeding is not a trivial complication, but is associated with poor 
outcome –also after adjusting for confounding factors65. Recent 
treatment with antiplatelet drugs is one factor that increases the 
bleeding risk, although far from all of these patients are subject to this 
complication73 113. This may in part be related to a variable response of 
platelet inhibition, which is well-characterized in clopidogrel-treated 
ACS patients114.  
Previous studies of thienopyridine-treated ACS patients have shown 
that preoperative PFT using impedance aggregometry can predict 
excessive bleeding. These studies have suggested a cut-off level of ADP-
dependent platelet aggregation of 22 or 30 U, to identify patients with 
an increased risk of bleeding48 77. 
5.1 Recovery of platelet function 
The pharmacokinetics of ticagrelor have been reported in several studies 
based on healthy volunteers115 or patients with stable atherosclerotic 
disease71 116. In paper I, we reported platelet recovery after 
discontinuation in ACS patients, and as expected, the mean platelet 
function gradually increased after discontinuation. Despite this 
seemingly predictable recovery, there was considerable variation in 
individual patients. A relatively narrow range of aggregation was 
observed at 12 h after discontinuation (0–24 U), but with increasing 
ranges at each subsequent time point. At 72 h, the ADP-induced 
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aggregation ranged from 4 to 88 U, and 6 of 24 patients (25%) had an 
aggregation below 22 U, indicating a possible increased risk of severe 
bleeding.  
A slight increase in AA- and TRAP-induced aggregation after 
discontinuation of ticagrelor was also observed, illustrating the partial 
dependence on P2Y12 signalling in these responses also117. The increase 
in AA-induced aggregation was only very minor, which can be 
explained by continuous treatment with aspirin throughout the study 
period. 
The variable recovery of ADP-dependent aggregation in ACS patients 
was confirmed in paper II, where platelet function was measured at 
different discontinuation times. Grouping of these observations 
depending on time since last dose of ticagrelor resulted in a gradual 
increase in mean values (Figure 10 A), although individual 
measurements at comparable discontinuation times had a wide spread –
resulting in some patients with a short time since discontinuation 
having a high platelet aggregation and vice versa (Figure 10 B). 
These studies do not explain the reason for the variability, but it is 
probably related to differences in patients’ clearance of the drug. Unlike 
clopidogrel, ticagrelor does not require metabolism for activation, 
although hepatic CYP-450 activity is needed for its clearance115. This 
activity may be reduced for a number of reasons, including chronic liver 
disease, interactions with other drugs, and dietary factors. If CYP-450 
activity is diminished, the overall antiplatelet activity would not be 
reduced as is the case in clopidogrel treatment118 119, but might very well 
be increased or prolonged due to impaired clearance. Indeed, one study 
of volunteers with mild hepatic impairment receiving a single dose of 
ticagrelor reported modest, but significantly higher exposure to 
ticagrelor and an active metabolite than in healthy control subjects120.  
5.2 Predicting the risk of bleeding 
With such a variability in platelet recovery, these data suggest that PFT 
may improve the assessment of the operative risk when ticagrelor-
treated patients are considered for surgery. This was confirmed in paper 
II, showing that the preoperative ADP-induced platelet aggregation 
capacity predicted the risk of severe bleeding complications in cardiac 
surgery patients treated with ticagrelor < 5 days before surgery. 
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The accuracy of ADP-induced platelet aggregability tested immediately 
before cardiac surgery to predict severe bleeding was acceptable, but 
not perfect (AUC under the ROC curve 0.73), underscoring the multi-
factorial nature of perioperative bleeding complications.  
Due to the individual variation in recovery of platelet function, the use 
of PFT may be superior to using time alone for optimal timing in high-
risk patients. The logistic regression model of the preoperative ADP test 
estimating the risk of severe bleeding (Figure 13) can be used to 
estimate the bleeding risk in an individual patient after the PFT result is 
obtained. This risk of bleeding, and associated morbidity and mortality, 
can then be weighed against the risk associated with postponing 
surgery.  
The results from this study are supported by previous observations in 
thienopyridine-treated patients, where preoperative PFT also predicted 
bleeding48 77. After the publication of paper II, another study of 149 
patients undergoing CABG within 48 hours of discontinuation of P2Y12 
inhibitor (clopidogrel, n = 80; prasugrel, n = 28; ticagrelor, n = 41) was 
reported. Preoperative PFT was performed using four different 
methods, including LTA and impedance aggregometry using the ADP 
test. Although this study did not provide a cut-off for bleeding or define 
the optimal PFT, the results strongly suggested a decrease in bleeding 
with increasing ADP-dependent platelet reactivity. 
The optimal cut-off value for ADP-dependent aggregation to detect 
bleeding risk in our study (22 U) was the same as the cut-off value in a 
previous study of thienopyridine-treated patients48. We used Youden’s 
index to define the optimal cut-off value. A limitation of this method is 
that a false negative (i.e. a falsely predicted non-bleeder) and false 
positive (i.e. a falsely predicted severe bleeder) are given the same 
statistical weight. In clinical practice, a false-negative value may confer 
greater risk in the management of patients, and a higher cut-off value 
may therefore be considered. 
5.3 Platelet transfusion in ticagrelor-treated 
ACS patients 
If ACS patients with DAPT are stable and at low risk of ischaemia, 
surgery should be postponed until the effect of antiplatelet therapy 
wears off. If the clinical situation requires acute surgery, measures 
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should be taken to minimize the risk of bleeding and transfusions. This 
includes meticulous surgical techniques, using a cell-saver device, 
minimizing CPB priming volumes, using antifibrinolytics, and 
optimizing secondary haemostasis. Ideally, an antidote for antiplatelet 
drugs would also be used. Although a successful antidote for ticagrelor 
has been reported in mice (Buchanon 2015), none is yet available for 
clinical use.  
In both paper I and paper III, platelet supplementation with clinically 
relevant doses did not result in any significant improvement in ADP-
induced aggregation, but large increases in AA-induced aggregation, in 
line with the results of previous studies121 122. However, the results from 
paper I expand the previous findings, showing no effect on ADP-
induced aggregation up to four days after discontinuation of ticagrelor.  
The lack of effect on ADP-induced aggregation might be explained by 
remaining plasma concentrations of ticagrelor or its metabolites, which 
may inhibit the supplemented platelets. Also, over time, storage of 
platelets diminishes the capacity for ADP-induced aggregation, limiting 
the possible improvement in this platelet signalling pathway after 
platelet transfusion123. 
Although these results indicate that the use of stored platelets is not a 
good antidote to ticagrelor, its use may still be beneficial. Most patients 
will have impaired AA-dependent aggregation due to treatment with 
ASA, but this will be greatly improved after platelet transfusion.  
5.4 Antifibrinolytics in ticagrelor-treated ACS 
patients 
Two classes of antifibrinolytic agents, the serine protease inhibitor 
aprotinin and the lysine analogues TA and EACA, have gained 
widespread acceptance and use in cardiac surgery. Similar to lysine 
analogues, aprotinin is a potent inhibitor of plasmin formation, but it 
also has additional effects. After the withdrawal and ensuing re-
introduction of aprotinin, lysine analogues have continued to dominate 
the market, with EACA being used predominantly in the United 
States124. Although aprotinin appears to be more effective than the 
lysine analogues in minimizing postoperative blood loss101, it remains 
unclear which patients might benefit from this treatment. Patients with 
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ongoing or recently stopped DAPT have an increased bleeding risk and 
may thus be a group that would benefit from aprotinin treatment. 
The main finding of paper III was that aprotinin, but not TA, improved 
ADP-induced platelet aggregation in patients with ongoing treatment 
with aspirin and ticagrelor. The results were independent of 
concomitant platelet concentrate supplementation. Although the 
absolute improvement in ADP-dependent aggregation was limited, data 
from paper II show that even small improvements in platelet function 
can reduce the bleeding risk, especially if baseline platelet function is 
poor (Figure 13).  
In this study, we could not identify the mechanism responsible for the 
improved platelet function. Aprotinin, which is a more complex 
molecule than TA, has several additional biological effects95, but there 
are no data showing a direct interaction between aprotinin and the 
P2Y12 receptor. Future mechanistic studies are needed to clarify this. 
5.5 DAPT after CABG surgery 
Current guidelines recommend that DAPT should be resumed as soon 
as possible after CABG69 90. These recommendations are based on 
limited evidence, as indicated by a C level of evidence. The results of 
paper IV support the idea that ACS patients benefit from DAPT after 
CABG. However, the benefit of DAPT was mainly due to the low 
mortality observed in patients treated with ticagrelor + ASA –both 
compared to ASA only, and compared to ASA + clopidogrel. The latter 
result was very much in line with the results from the CABG sub-study 
in the PLATO trial41, where ticagrelor + ASA was found to be 
associated with a 50% reduction in all-cause one-year mortality 
compared to clopidogrel + ASA.  
The benefit of ticagrelor treatment in ACS compared to clopidogrel was 
also supported by a recent study based on 45,073 patients from the 
SWEDEHEART registry125. However, this study did not include 
patients undergoing CABG, which was the subject of paper IV. When 
the results of these two SWEDEHEART studies are compared, another 
pattern from the PLATO study is supported: ACS patients undergoing 
CABG appeared to have the greatest survival benefit from ticagrelor 
treatment. In the SWEDEHEART study of ACS patients treated 
medically or with PCI, the adjusted HR for death at two years was 0.85 
Cardiac surgery and antiplatelet therapy 
48 
(95% CI 0.78–0.93), whereas the adjusted hazard ratio for death at one 
year was 0.36 (95% CI 0.15‒0.89) in paper IV. 
The adherence to the recommendation of DAPT after CABG in ACS 
patients was relatively low, with only 26% of ACS patients being 
treated with DAPT after CABG. One can speculate that the lack of 
strong evidence, the fear of bleeding complications, and the tradition of 
using ASA only after CABG contribute to surgeons’ resistance to 
prescribe DAPT after CABG. In the Synergy between Percutaneous 
Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) 
study, where approximately one-third of the patients had ACS, only 
20% of CABG patients were treated with DAPT at discharge, as 
compared to 97% in the PCI group91. It is possible that increased use of 
ticagrelor would improve the long-term outcome after CABG in 
patients with ACS. 
5.6 Limitations of the studies 
Haemostasis is a complex process involving the interaction of 
complicated systems. A single laboratory test can give important 
information, but cannot be expected to reflect the entire process. We 
used only MEA to assess platelet function, albeit with multiple agonists 
to activate different platelet signalling pathways. This method does not 
take into consideration possible platelet interactions with blood vessels, 
vascular endothelium, or rheological factors. Tests can be influenced by 
platelet count, and reliable results require a platelet count of > 100 × 
109/L126, which was the case in all patients in papers I–III at the time of 
aggregometry. 
However, the MEA testing is reproducible, uses whole-blood sampling, 
and allows study conditions to be standardized. Other PFTs might give 
somewhat different results, but it has been shown that there is a 
satisfactory correlation between MEA and LTA, which is considered the 
golden standard method.  MEA  is also a point-of-care device that is 
easily adopted in clinical practice. 
The ex vivo models for platelet and drug supplementation used in 
papers I and III are simplified and do not take into consideration the 
effect of surgical trauma or CPB. Other studies of platelet 
supplementation have used autologous platelet-rich plasma, but we 
deliberately chose to use ABO-compatible apheresis platelet concentrate 
from the hospital blood bank, which reflects the clinical situation more 
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closely. Ideally, the results from these studies should be confirmed in 
clinical in vivo studies.   
In paper II, the study was not performed blind; therefore, knowledge of 
both the time since the last dose of ticagrelor and of the preoperative 
impedance aggregometry results might have influenced clinical 
handling, including surgical management and postoperative 
transfusions, especially regarding platelet transfusions. The results and 
conclusions are applicable only to the study population (i.e. ACS 
patients with ticagrelor treatment within 5 days before CABG). In other 
populations, other factors may be equally, or more important to predict 
bleeding complications. 
As paper IV was an observational study, the issue of selection bias was 
addressed by propensity score matching. However, it is only possible to 
match or adjust for patient characteristics that are known and included 
in the data. Thus, a limitation was unmeasured or unknown factors that 
were not accounted for (residual confounding). Another limitation was 
missing registry data in certain variables, which could possibly have 
influenced the results. 
The registry data did not include information on morbidity after the 
initial hospitalization, including bleeding and thromboembolic 
complications during the 12-month study period. Furthermore, no data 
were available on preoperative antiplatelet therapy, the length of 
treatment with the P2Y12 inhibitor, compliance with the prescription, 
and causes of deaths.  
Ideally, the results of paper IV should be confirmed in a well-designed 
prospective randomized trial comparing ASA + ticagrelor with ASA 
alone, or with clopidogrel + ASA, after CABG. Pending the results of 
such a trial, this study had some merits and a number of strengths. It 
included a nationwide dataset with a large number of patients and the 
data contained a large number of relevant and relatively complete 
variables with none of the patients being lost to follow-up. 
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6  CONCLUSIONS 
1. There is a large degree of inter-individual variability in 
recovery of ADP-induced platelet aggregation after 
discontinuation of ticagrelor in ACS patients awaiting 
CABG.  
2. Administration of platelet concentrate does not improve 
ADP-induced aggregation after discontinuation of 
ticagrelor. Platelet concentrate markedly improves ADP-
induced aggregation in patients with ongoing ASA 
treatment. 
3. The use of platelet function tests can predict severe 
bleeding complications in ticagrelor-treated cardiac 
surgery patients. 
4. Aprotinin improves the ADP-dependent platelet 
aggregation in ticagrelor treated ACS patients. 
Tranexamic acid was not associated with any 
improvement in platelet function. 
5. Less than 30% of ACS patients in Sweden currently 
discharged with DAPT after CABG surgery. 
6. Postoperative antiplatelet therapy may influence 
survival after CABG in patients with ACS. DAPT with 
ticagrelor and ASA is associated with improved one-
year survival.  
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